Fosamax and Osteonecrosis of the Jaw: A Review of Causation and Risk

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

Legacy Context and Transition to Specialized Risk

The legacy heritage of this domain is rooted in the dissemination of general health and science information, providing a broad foundation for public understanding of medical topics. Within this context, the focus has historically encompassed a wide range of conditions and treatments, including those related to bone health and pharmaceutical interventions. As the informational landscape evolves, a natural progression emerges toward more specialized areas of inquiry, particularly those that intersect with occupational and environmental health. This pivot is exemplified by the transition from general health discussions to the specific concern of Fosamax exposure and its potential association with osteonecrosis of the jaw. The shift acknowledges that while general health information serves a vital role, there is a growing need to address risks that may arise in particular settings, such as prolonged medication use in clinical or occupational contexts. This transition does not delve into mechanistic claims but rather reframes the inquiry to highlight the importance of understanding exposure risks within professional environments. By moving from a broad health science perspective to a focused examination of Fosamax-related risks, the domain can better serve audiences seeking clarity on how such exposures may impact health outcomes in specific scenarios.

Bridge to Fosamax and Osteonecrosis of the Jaw

Building on the legacy of general health information, this section bridges to the specific medical literature on Fosamax (alendronate) and its association with osteonecrosis of the jaw (ONJ). Fosamax is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its mechanism involves increasing bone mass and reducing fracture incidence, including hip and spine fractures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, a recognized adverse effect associated with bisphosphonates, including Fosamax, is osteonecrosis of the jaw (ONJ). ONJ is a condition characterized by exposed, non-healing bone in the jaw, which can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The clinical presentation involves bone exposure in the oral cavity, often accompanied by pain, swelling, and infection. Diagnosis is typically based on clinical examination and history, with imaging used to assess extent.

Risk Factors and Mechanisms

Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The mechanistic pathways linking Fosamax to ONJ are not fully elucidated but involve the drug's potent inhibition of osteoclast-mediated bone resorption. Bisphosphonates like alendronate accumulate in bone, particularly in areas of high turnover such as the jaw, and suppress remodeling. This suppression can impair the jawbone's ability to repair microdamage and respond to local stressors like infection or dental procedures. Multiscale characterization of jawbone has provided comprehensive information to help understand jawbone-specific responses to bone-related complications, including bisphosphonate-related ONJ (https://pubmed.ncbi.nlm.nih.gov/40345077/). The resulting avascular necrosis is thought to arise from a combination of reduced bone turnover, compromised blood supply, and local infection or trauma.

Temporal Association and Dose-Response Evidence

Regarding the timeline between exposure and documented harm, the time to onset of symptoms varied from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, in placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). A cohort study among female patients treated for osteoporosis in the United Kingdom Clinical Practice Research Datalink found that ONJ risk was threefold higher after 2-3 years of treatment and eightfold higher after 10 years compared with past use, though absolute risks remained low (approximately 0.05% after 5 years) and diminished after discontinuation (https://pubmed.ncbi.nlm.nih.gov/39400702/). This suggests a cumulative dose-response relationship, with longer exposure conferring greater risk.

Adequacy of Warnings and Causation Considerations

Adequacy of warnings regarding Fosamax and ONJ is addressed in the prescribing information. The label includes a specific warning under Section 5.4, "Osteonecrosis of the Jaw," which states that ONJ has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The label also notes that for patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Additionally, the label advises discontinuing use if severe symptoms develop, and notes that most patients had relief of symptoms after stopping, though a subset had recurrence when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The limitations of use section also notes that the optimal duration of use has not been determined, and for low-risk patients, drug discontinuation after 3 to 5 years may be considered (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Causation-related considerations for affected patients involve establishing a temporal relationship between Fosamax use and ONJ onset, excluding other etiologies such as cancer or radiation therapy, and assessing risk factors. The label acknowledges that ONJ can occur spontaneously but is generally associated with dental procedures or local infection (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The cohort study data support a dose-response relationship, with risk increasing with longer treatment duration (https://pubmed.ncbi.nlm.nih.gov/39400702/). For patients who develop ONJ, management typically involves discontinuation of the bisphosphonate, conservative dental care, and treatment of infection. The label notes that most patients had relief of symptoms after stopping the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In summary, Fosamax is associated with a rare but serious risk of ONJ, with evidence supporting a causal relationship through biological plausibility, temporal association, and dose-response data. The prescribing information provides warnings and guidance for risk mitigation, including dental evaluation and consideration of drug discontinuation for invasive procedures. Patients and clinicians should weigh the benefits of fracture reduction against the low absolute risk of ONJ, particularly with long-term use.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.

Frequently Asked Questions

What is osteonecrosis of the jaw (ONJ) and how is it related to Fosamax?

Osteonecrosis of the jaw (ONJ) is a condition characterized by exposed, non-healing bone in the jaw, often associated with tooth extraction or local infection. Fosamax (alendronate), a bisphosphonate, has been linked to ONJ as a rare but serious adverse effect. The drug suppresses bone remodeling, which can impair the jawbone's ability to repair microdamage, especially after dental procedures. The prescribing information includes a specific warning about ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

What are the risk factors for developing ONJ while taking Fosamax?

Risk factors include invasive dental procedures (e.g., tooth extraction, dental implants), cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid conditions like periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures. The risk increases with longer duration of bisphosphonate use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

How strong is the evidence linking Fosamax to ONJ?

Evidence includes biological plausibility (bisphosphonates inhibit bone remodeling), temporal association (symptoms can appear within days to months of starting the drug), and dose-response data (a cohort study found risk threefold higher after 2-3 years and eightfold higher after 10 years of treatment) (https://pubmed.ncbi.nlm.nih.gov/39400702/). The FDA label acknowledges the association and provides risk mitigation guidance.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.